Qinghai Spring Medicinal Resources Technology Co., Ltd. Logo

Qinghai Spring Medicinal Resources Technology Co., Ltd.

600381.SS

(0.8)
Stock Price

3,27 CNY

-23.66% ROA

-21.49% ROE

-6.16x PER

Market Cap.

1.692.528.459,00 CNY

1.37% DER

0% Yield

-113.69% NPM

Qinghai Spring Medicinal Resources Technology Co., Ltd. Stock Analysis

Qinghai Spring Medicinal Resources Technology Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (1%), which means it has a small amount of debt compared to the ownership it holds

2 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (72) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

3 ROE

The stock's ROE indicates a negative return (-18.83%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-19.6%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 PBV

The stock's elevated P/BV ratio (3.24x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

10 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

11 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Qinghai Spring Medicinal Resources Technology Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Revenue
Year Revenue Growth
1998 129.790.544
1999 92.784.251 -39.88%
2000 104.294.586 11.04%
2001 142.992.748 27.06%
2002 303.165.426 52.83%
2003 443.200.616 31.6%
2004 990.498.358 55.25%
2005 585.280.377 -69.23%
2006 86.416.756 -577.28%
2007 9.602.518 -799.94%
2008 40.721.644 76.42%
2009 53.030.617 23.21%
2010 61.371.358 13.59%
2011 238.803.643 74.3%
2012 514.260.599 53.56%
2013 4.167.458 -12239.91%
2014 29.902.525 86.06%
2015 1.401.689.319 97.87%
2016 708.130.160 -97.94%
2017 471.117.193 -50.31%
2018 333.018.482 -41.47%
2019 233.746.329 -42.47%
2020 124.266.266 -88.1%
2021 127.764.006 2.74%
2022 160.178.078 20.24%
2023 213.156.326 24.85%
2023 213.876.676 0.34%
2024 211.263.016 -1.24%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 12.493.374 100%
2013 27.644.212 54.81%
2014 8.037.129 -243.96%
2015 10.206.170 21.25%
2016 9.090.547 -12.27%
2017 2.029.838 -347.85%
2018 3.036.810 33.16%
2019 4.498.472 32.49%
2020 12.298.196 63.42%
2021 9.538.458 -28.93%
2022 11.377.981 16.17%
2023 17.210.981 33.89%
2023 11.639.463 -47.87%
2024 22.229.920 47.64%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Qinghai Spring Medicinal Resources Technology Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 15.208.917
1999 10.326.481 -47.28%
2000 11.915.868 13.34%
2001 16.751.949 28.87%
2002 21.983.874 23.8%
2003 18.847.155 -16.64%
2004 39.183.342 51.9%
2005 69.463.980 43.59%
2006 152.029.698 54.31%
2007 5.018.347 -2929.48%
2008 17.010.227 70.5%
2009 17.144.997 0.79%
2010 12.743.910 -34.53%
2011 23.327.212 45.37%
2012 33.342.065 30.04%
2013 39.651.067 15.91%
2014 38.631.914 -2.64%
2015 12.864.238 -200.3%
2016 20.847.815 38.29%
2017 14.495.071 -43.83%
2018 13.089.551 -10.74%
2019 14.089.728 7.1%
2020 17.753.240 20.64%
2021 12.040.642 -47.44%
2022 14.249.814 15.5%
2023 102.674.195 86.12%
2023 20.773.125 -394.26%
2024 -10.073.998 306.21%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Qinghai Spring Medicinal Resources Technology Co., Ltd. EBITDA
Year EBITDA Growth
1998 29.496.177
1999 32.287.779 8.65%
2000 28.496.504 -13.3%
2001 37.360.823 23.73%
2002 52.511.691 28.85%
2003 75.078.574 30.06%
2004 145.588.103 48.43%
2005 -76.552.007 290.18%
2006 -666.203.063 88.51%
2007 44.097.427 1610.75%
2008 20.533.737 -114.76%
2009 105.029.124 80.45%
2010 78.089.494 -34.5%
2011 146.055.759 46.53%
2012 4.565.469 -3099.14%
2013 159.172.863 97.13%
2014 148.642.685 -7.08%
2015 470.432.859 68.4%
2016 324.174.401 -45.12%
2017 193.545.367 -67.49%
2018 111.870.057 -73.01%
2019 48.244.442 -131.88%
2020 21.233.056 -127.21%
2021 -108.828.319 119.51%
2022 -133.422.065 18.43%
2023 -68.351.441 -95.2%
2023 -195.207.953 64.99%
2024 -91.408.640 -113.56%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Gross Profit
Year Gross Profit Growth
1998 46.472.564
1999 39.513.394 -17.61%
2000 34.416.200 -14.81%
2001 50.100.416 31.31%
2002 65.644.119 23.68%
2003 70.994.164 7.54%
2004 211.283.297 66.4%
2005 148.502.279 -42.28%
2006 44.543.506 -233.39%
2007 363.843 -12142.51%
2008 19.944.587 98.18%
2009 26.813.553 25.62%
2010 31.588.506 15.12%
2011 128.991.651 75.51%
2012 23.305.170 -453.49%
2013 2.501.221 -831.75%
2014 2.279.413 -9.73%
2015 677.215.444 99.66%
2016 340.565.686 -98.85%
2017 213.834.585 -59.27%
2018 98.718.512 -116.61%
2019 64.997.121 -51.88%
2020 23.733.817 -173.86%
2021 25.211.819 5.86%
2022 73.860.731 65.87%
2023 147.194.410 49.82%
2023 130.919.629 -12.43%
2024 30.211.628 -333.34%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Net Profit
Year Net Profit Growth
1998 9.724.105
1999 15.496.311 37.25%
2000 17.643.761 12.17%
2001 19.468.512 9.37%
2002 20.658.305 5.76%
2003 27.557.871 25.04%
2004 18.861.585 -46.11%
2005 -160.346.704 111.76%
2006 -558.375.578 71.28%
2007 50.731.273 1200.65%
2008 117.046.289 56.66%
2009 51.462.069 -127.44%
2010 53.582.585 3.96%
2011 92.611.641 42.14%
2012 -133.230.816 169.51%
2013 32.859.879 505.45%
2014 79.356.632 58.59%
2015 357.575.992 77.81%
2016 244.960.927 -45.97%
2017 310.542.224 21.12%
2018 68.446.859 -353.7%
2019 5.807.775 -1078.54%
2020 -319.544.171 101.82%
2021 -248.610.920 -28.53%
2022 -287.550.326 13.54%
2023 -78.962.058 -264.16%
2023 -267.865.267 70.52%
2024 -131.859.424 -103.14%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 -1 100%
2006 -4 75%
2007 0 0%
2008 1 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 -1 0%
2013 0 0%
2014 1 0%
2015 1 0%
2016 0 0%
2017 1 0%
2018 0 0%
2019 0 0%
2020 -1 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Free Cashflow
Year Free Cashflow Growth
1999 18.344.312
2000 -37.615.257 148.77%
2001 -65.627.322 42.68%
2002 -55.487.476 -18.27%
2003 -104.063.546 46.68%
2004 20.976.434 596.1%
2005 161.280.171 86.99%
2006 21.566.844 -647.82%
2007 6.980.614 -208.95%
2008 7.089.347 1.53%
2009 8.722.833 18.73%
2010 -303.232.307 102.88%
2011 36.570.345 929.18%
2012 -881.514.914 104.15%
2013 -104.558.882 -743.08%
2014 -214.722.918 51.31%
2015 816.911.593 126.28%
2016 319.571.130 -155.63%
2017 75.003.799 -326.07%
2018 -227.482.351 132.97%
2019 -241.585.006 5.84%
2020 -275.586.530 12.34%
2021 -185.727.897 -48.38%
2022 -32.644.057 -468.95%
2023 30.447.405 207.21%
2023 10.385.379 -193.18%
2024 3.266.740 -217.91%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
1999 70.277.352
2000 4.519.366 -1455.03%
2001 -10.643.767 142.46%
2002 15.539.201 168.5%
2003 1.426.370 -989.42%
2004 33.828.361 95.78%
2005 162.116.152 79.13%
2006 21.566.844 -651.69%
2007 6.996.114 -208.27%
2008 20.828.464 66.41%
2009 39.161.460 46.81%
2010 71.473.341 45.21%
2011 249.975.574 71.41%
2012 -701.182.824 135.65%
2013 -28.090.593 -2396.15%
2014 -89.638.611 68.66%
2015 832.165.160 110.77%
2016 344.988.734 -141.22%
2017 95.735.928 -260.35%
2018 -183.969.888 152.04%
2019 -236.299.693 22.15%
2020 -77.950.990 -203.14%
2021 -63.933.807 -21.92%
2022 -31.821.163 -100.92%
2023 33.433.411 195.18%
2023 23.916.780 -39.79%
2024 3.466.756 -589.89%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
1999 51.933.039
2000 42.134.623 -23.26%
2001 54.983.555 23.37%
2002 71.026.677 22.59%
2003 105.489.916 32.67%
2004 12.851.927 -720.81%
2005 835.981 -1437.35%
2006 0 0%
2007 15.500 100%
2008 13.739.117 99.89%
2009 30.438.626 54.86%
2010 374.705.648 91.88%
2011 213.405.228 -75.58%
2012 180.332.090 -18.34%
2013 76.468.289 -135.83%
2014 125.084.307 38.87%
2015 15.253.567 -720.03%
2016 25.417.604 39.99%
2017 20.732.129 -22.6%
2018 43.512.463 52.35%
2019 5.285.312 -723.27%
2020 197.635.540 97.33%
2021 121.794.090 -62.27%
2022 822.895 -14700.7%
2023 2.986.006 72.44%
2023 13.531.401 77.93%
2024 200.016 -6665.16%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Equity
Year Equity Growth
1998 93.867.019
1999 113.379.076 17.21%
2000 117.797.849 3.75%
2001 333.975.975 64.73%
2002 351.788.262 5.06%
2003 391.638.950 10.18%
2004 489.707.165 20.03%
2005 327.767.660 -49.41%
2006 -429.596.423 176.3%
2007 -362.395.841 -18.54%
2008 -230.813.399 -57.01%
2009 -178.115.253 -29.59%
2010 -116.100.653 -53.41%
2011 2.318.011.936 105.01%
2012 2.152.074.082 -7.71%
2013 50.034.356 -4201.19%
2014 308.443.221 83.78%
2015 1.758.383.871 82.46%
2016 2.003.787.302 12.25%
2017 2.319.909.314 13.63%
2018 2.382.827.815 2.64%
2019 2.388.635.591 0.24%
2020 2.069.091.420 -15.44%
2021 1.820.480.500 -13.66%
2022 1.532.930.174 -18.76%
2023 1.464.353.754 -4.68%
2023 1.267.317.757 -15.55%
2024 1.196.335.651 -5.93%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Assets
Year Assets Growth
1998 213.348.872
1999 241.420.410 11.63%
2000 305.706.420 21.03%
2001 598.919.728 48.96%
2002 767.690.182 21.98%
2003 1.181.490.109 35.02%
2004 1.713.444.081 31.05%
2005 1.372.892.436 -24.81%
2006 433.779.071 -216.5%
2007 345.213.724 -25.66%
2008 358.210.840 3.63%
2009 347.488.536 -3.09%
2010 822.476.064 57.75%
2011 3.936.019.404 79.1%
2012 4.051.657.494 2.85%
2013 1.488.991.161 -172.11%
2014 1.435.219.586 -3.75%
2015 2.112.984.803 32.08%
2016 2.210.739.672 4.42%
2017 2.433.470.043 9.15%
2018 2.435.511.173 0.08%
2019 2.408.770.797 -1.11%
2020 2.206.170.959 -9.18%
2021 1.848.120.872 -19.37%
2022 1.559.229.152 -18.53%
2023 1.520.345.781 -2.56%
2023 1.359.312.015 -11.85%
2024 1.253.653.855 -8.43%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Liabilities
Year Liabilities Growth
1998 119.481.853
1999 128.041.333 6.68%
2000 187.908.571 31.86%
2001 264.943.752 29.08%
2002 415.901.919 36.3%
2003 789.851.157 47.34%
2004 1.223.736.914 35.46%
2005 1.045.124.775 -17.09%
2006 863.375.493 -21.05%
2007 707.609.565 -22.01%
2008 589.024.239 -20.13%
2009 525.603.788 -12.07%
2010 938.576.716 44%
2011 1.618.007.467 41.99%
2012 1.899.583.411 14.82%
2013 1.438.956.805 -32.01%
2014 1.126.776.365 -27.71%
2015 354.600.931 -217.76%
2016 206.952.369 -71.34%
2017 113.560.729 -82.24%
2018 52.683.357 -115.55%
2019 20.135.206 -161.65%
2020 137.079.538 85.31%
2021 27.640.371 -395.94%
2022 26.298.977 -5.1%
2023 55.992.027 53.03%
2023 91.994.257 39.14%
2024 56.568.203 -62.63%

Qinghai Spring Medicinal Resources Technology Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.42
Net Income per Share
-0.47
Price to Earning Ratio
-6.16x
Price To Sales Ratio
6.94x
POCF Ratio
25.99
PFCF Ratio
29.31
Price to Book Ratio
1.43
EV to Sales
6.31
EV Over EBITDA
-7
EV to Operating CashFlow
23.42
EV to FreeCashFlow
26.66
Earnings Yield
-0.16
FreeCashFlow Yield
0.03
Market Cap
1,69 Bil.
Enterprise Value
1,54 Bil.
Graham Number
4.65
Graham NetNet
0.46

Income Statement Metrics

Net Income per Share
-0.47
Income Quality
-0.24
ROE
-0.21
Return On Assets
-0.22
Return On Capital Employed
-0.22
Net Income per EBT
1.04
EBT Per Ebit
1
Ebit per Revenue
-1.09
Effective Tax Rate
-0.03

Margins

Sales, General, & Administrative to Revenue
0.09
Research & Developement to Revenue
0.06
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.47
Operating Profit Margin
-1.09
Pretax Profit Margin
-1.1
Net Profit Margin
-1.14

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.11
Free CashFlow per Share
0.1
Capex to Operating CashFlow
0.12
Capex to Revenue
0.03
Capex to Depreciation
0.27
Return on Invested Capital
-0.23
Return on Tangible Assets
-0.24
Days Sales Outstanding
82.94
Days Payables Outstanding
9.62
Days of Inventory on Hand
636.28
Receivables Turnover
4.4
Payables Turnover
37.93
Inventory Turnover
0.57
Capex per Share
0.01

Balance Sheet

Cash per Share
0,29
Book Value per Share
2,04
Tangible Book Value per Share
1.9
Shareholders Equity per Share
2.03
Interest Debt per Share
0.03
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
0.7
Current Ratio
13.44
Tangible Asset Value
1,11 Bil.
Net Current Asset Value
0,60 Bil.
Invested Capital
977400817
Working Capital
0,61 Bil.
Intangibles to Total Assets
0.07
Average Receivables
0,15 Bil.
Average Payables
0,00 Bil.
Average Inventory
239385396
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Dividends
Year Dividends Growth
2002 0
2003 0 0%

Qinghai Spring Medicinal Resources Technology Co., Ltd. Profile

About Qinghai Spring Medicinal Resources Technology Co., Ltd.

Qinghai Spring Medicinal Resources Technology Co., Ltd. research and development, production, and sale of cordyceps products. It is also involved in the sale of beverages and aquatic products; advertising; and foreign investment business. The company was founded in 2003 and is based in Xining, China.

CEO
Mr. Xuefeng Zhang
Employee
173
Address
Xining Eco and Techn Dev Zone
Xining, 810007

Qinghai Spring Medicinal Resources Technology Co., Ltd. Executives & BODs

Qinghai Spring Medicinal Resources Technology Co., Ltd. Executives & BODs
# Name Age
1 Mr. Xuefeng Zhang
Chairman & GM
70
2 Ms. Wang Lin
Financial Director
70

Qinghai Spring Medicinal Resources Technology Co., Ltd. Competitors